Avipero

Directions Website

MODIFYING CANCER PROGRESSION THROUGH
CELL REAIR and RESTORATION Our target was cellular repair.

AVIPERO Bio was founded by core scientific expertise with a keen interest in therapeutic disruptors in clinical indications where treatments stagnated due to misunderstood pathologies. AVIPERO Bio seeks to reimagine beta1 integrin targeting in oncology by deconvoluting its role in cancer cell behaviour. In irreversible injury and senescence models, AVIPERO identified beta1 integrin as a novel target for inducing repair and regeneration and reversing aging. Targeting the non-ligand binding part of beta1 integrin to allosterically preserve the receptor in its normal low affinity state (dimmer switch), reduces matrix stiffness and cellular stress and normalises cell cycle to allow normal aging. Beta1 Integrin is crucial for tumor metastasis and increased expression is associated with decreased survival advanced cancers. Ablation of beta1 integrin
in tumor cells reduces tumor cell proliferation and the acquisition of
cellular aging. Antibodies against beta1-integrin inhibited tumour growth in mouse models of breast cancer, prostate cancer, osteosarcoma and melanoma. Anti-beta1 integrin antibody inhibits metastasis of breast cancer.

09/29/2026

Please join us in welcoming Dr Neil Butt to the Avipero Bio Advisory Board.

Neil has spent 30 years helping promising new medicines make the journey from the laboratory to the companies that bring them to patients. He has led biotech companies including Orbit Discovery and IONTAS, and today runs his own consultancy, NBIO Consulting, in Oxford.

At Avipero, we're developing JB1a, an antibody designed to fine-tune a protein called β1 integrin so that diseased cells are restored rather than destroyed. Our work spans cancer, Parkinson's disease and arthritis. As we move JB1a towards clinical trials, Neil's experience will help us find the right partners to take it there.

Welcome to the team, Neil!

09/09/2026

Check out our updated website on

A Pharmaceutical Company Dedicated to harnessing integrin allostery for reversing malignancy.

06/24/2026

A single antibody dose cut Parkinson's motor asymmetry by ~50% in mice — by targeting something the field has overlooked.

Not α-synuclein. Not dopamine replacement. β1 integrin — the signalling hub governing neuronal survival.
Our new preprint is live on bioRxiv. In the 6-OHDA mouse model, one therapeutic dose of our anti-β1 integrin antibody JB1a, given 7 days post-lesion, returned animals to sham-control levels (p

05/06/2026

Robert J. Naylor — my husband, my work partner, my best friend, the father of our twins, and the finest human being I have ever known.
Three years ago today, on 7 May 2023 at about 19:15 I lost him.
Robert's scientific legacy is profound. His work at the University of Bradford mapped the dopamine pathways in the brain that govern movement and behaviour — a foundation that still underpins how we understand and treat Parkinson's disease today. His research on 5-HT3 receptor antagonists contributed to the discovery of ondansetron, the antiemetic that has spared countless cancer patients the worst of chemotherapy. With AVIPERO, he turned decades of neuropharmacology into a mission: to bring genuinely new therapeutics to the patients who need them most.
Beyond his science, Robert was an all-rounder in the truest sense. A devoted father. A steady, loving husband. A mentor and friend to so many. His Yorkshire sense of humour was iconic!
The blessing of having him in our lives is long lasting. It lives in our daughters, in the science he leaves behind, in the people he shaped, and in the work we continue in his name.
I am still grieving for him, and I will be — until I meet him again.
To everyone who has held us, remembered him, and carried his memory forward these past three years: thank you. He is missed beyond words, and loved beyond measure.

Address

Wilmington, Delaware.
Wilmington, DE

Website

http://www.avipero.com/

Alerts

Be the first to know and let us send you an email when Avipero posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.